Diagnosis and management of multiple myeloma: a review

AJ Cowan, DJ Green, M Kwok, S Lee, DG Coffey… - Jama, 2022 - jamanetwork.com
Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …

[HTML][HTML] Multiple myeloma current treatment algorithms

SV Rajkumar, S Kumar - Blood cancer journal, 2020 - nature.com
The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results …

M Dimopoulos, H Quach, MV Mateos, O Landgren… - The Lancet, 2020 - thelancet.com
Background Lenalidomide and bortezomib frontline exposure has raised a growing need for
novel treatments for patients with relapsed or refractory multiple myeloma. Carfilzomib in …

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

N Raje, K Anderson, H Einsele, Y Efebera, F Gay… - Blood cancer …, 2023 - nature.com
Bispecific antibodies (BsAbs) are emerging as an important novel class of
immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be …

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

NS Raje, E Anaissie, SK Kumar, S Lonial… - The Lancet …, 2022 - thelancet.com
Infection remains the leading cause of morbidity and mortality in patients with multiple
myeloma because of the cumulative effect of disease, treatment, and host-related factors …

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

E Terpos, M Engelhardt, G Cook, F Gay, MV Mateos… - Leukemia, 2020 - nature.com
Patients with multiple myeloma (MM) seem to be at increased risk for more severe COVID-
19 infection and associated complications due to their immunocompromised state, the older …

[HTML][HTML] Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients …

G Cook, AJ Ashcroft, G Pratt, R Popat… - British journal of …, 2020 - ncbi.nlm.nih.gov
3. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-
1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress …

Recommendations on prevention of infections during chimeric antigen receptor T‐cell and bispecific antibody therapy in multiple myeloma

M Mohan, R Chakraborty, S Bal… - British Journal of …, 2023 - Wiley Online Library
Chimeric antigen receptor T (CAR T) cell and bispecific antibody therapies have shown
unprecedented efficacy in heavily pretreated patients with multiple myeloma (MM). However …

Current approaches to management of newly diagnosed multiple myeloma

U Goel, S Usmani, S Kumar - American journal of hematology, 2022 - Wiley Online Library
Major developments in the treatment of multiple myeloma (MM) over the past decade have
led to a continued improvement in survival. Significant progress has been made with deeper …

How I treat AL amyloidosis

G Palladini, G Merlini - Blood, The Journal of the American …, 2022 - ashpublications.org
The treatment of patients with systemic light chain (AL) amyloidosis is a challenge to
hematologists. Despite its generally small size, the underlying clone causes a rapidly …